AdvanCell, a clinical stage radiopharmaceutical company developing targeted alpha therapies for cancer, has closed a $315.0M Series D funding round. The significant capital infusion was backed by investors Ally Bridge Group and Alpha Wave Global.
The company's innovative pipeline focuses on 212Pb-based treatments, with its platform technology designed to address the critical challenge of reliably supplying the necessary isotope for these advanced therapies.


















